Bifogade filer
Kurs & Likviditet
Kalender
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-08-13 | Kvartalsrapport 2024-Q2 |
2024-05-15 | Ordinarie utdelning MOB 0.00 SEK |
2024-05-14 | Årsstämma 2024 |
2024-05-07 | Kvartalsrapport 2024-Q1 |
2024-02-13 | Bokslutskommuniké 2023 |
2023-11-07 | Kvartalsrapport 2023-Q3 |
2023-10-09 | Extra Bolagsstämma 2023 |
2023-08-03 | Kvartalsrapport 2023-Q2 |
2023-05-24 | Split MOB 10:1 |
2023-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2023-05-16 | Årsstämma 2023 |
2023-05-09 | Kvartalsrapport 2023-Q1 |
2023-02-07 | Bokslutskommuniké 2022 |
2022-11-08 | Kvartalsrapport 2022-Q3 |
2022-08-09 | Kvartalsrapport 2022-Q2 |
2022-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2022-05-16 | Årsstämma 2022 |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-05-03 | Extra Bolagsstämma 2022 |
2022-02-08 | Bokslutskommuniké 2021 |
2021-11-09 | Kvartalsrapport 2021-Q3 |
2021-08-10 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-03-31 | Ordinarie utdelning MOB 0.00 SEK |
2021-03-30 | Årsstämma 2021 |
2021-02-09 | Bokslutskommuniké 2020 |
2020-12-01 | Extra Bolagsstämma 2020 |
2020-05-12 | Kvartalsrapport 2020-Q3 |
2020-02-11 | Kvartalsrapport 2020-Q2 |
2019-11-19 | Kvartalsrapport 2020-Q1 |
2019-11-04 | Inlösen MOB 46.5 |
2019-10-31 | Ordinarie utdelning MOB 0.00 SEK |
2019-10-30 | Årsstämma 2020 |
2019-08-29 | Bokslutskommuniké 2019 |
2019-05-16 | Ordinarie utdelning MOB 0.00 SEK |
2019-05-15 | Årsstämma 2019 |
2019-05-14 | Kvartalsrapport 2019-Q1 |
2019-03-15 | Extra Bolagsstämma 2019 |
2019-02-12 | Bokslutskommuniké 2018 |
2018-11-06 | Kvartalsrapport 2018-Q3 |
2018-08-07 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Ordinarie utdelning MOB 0.00 SEK |
2018-05-15 | Årsstämma 2018 |
2018-05-08 | Kvartalsrapport 2018-Q1 |
2018-02-13 | Bokslutskommuniké 2017 |
2017-11-13 | Kvartalsrapport 2017-Q3 |
2017-08-08 | Kvartalsrapport 2017-Q2 |
2017-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2017-05-16 | Årsstämma 2017 |
2017-05-09 | Kvartalsrapport 2017-Q1 |
2017-02-14 | Bokslutskommuniké 2016 |
2016-11-08 | Kvartalsrapport 2016-Q3 |
2016-08-09 | Kvartalsrapport 2016-Q2 |
2016-05-19 | Ordinarie utdelning MOB 0.00 SEK |
2016-05-18 | Årsstämma 2016 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-02-17 | Bokslutskommuniké 2015 |
2015-11-10 | Kvartalsrapport 2015-Q3 |
2015-08-11 | Kvartalsrapport 2015-Q2 |
2015-05-12 | Ordinarie utdelning MOB 0.00 SEK |
2015-05-11 | Årsstämma 2015 |
2015-05-11 | Bokslutskommuniké 2014 |
2015-05-11 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-11-14 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Kvartalsrapport 2014-Q2 |
2014-05-14 | Ordinarie utdelning MOB 0.00 SEK |
2014-05-13 | Årsstämma 2014 |
2014-05-13 | Kvartalsrapport 2014-Q1 |
2014-02-20 | Bokslutskommuniké 2013 |
2013-11-05 | Kvartalsrapport 2013-Q3 |
2013-08-06 | Kvartalsrapport 2013-Q2 |
2013-05-21 | Kvartalsrapport 2013-Q1 |
2013-05-21 | Analytiker möte 2013 |
2013-04-24 | Ordinarie utdelning MOB 0.00 SEK |
2013-04-23 | Årsstämma 2013 |
2013-03-13 | 15-7 2013 |
2013-02-05 | Bokslutskommuniké 2012 |
2012-11-19 | Extra Bolagsstämma 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-09-20 | Kapitalmarknadsdag 2012 |
2012-08-28 | Kvartalsrapport 2012-Q2 |
2012-06-11 | 15-7 2012 |
2012-04-24 | Ordinarie utdelning MOB 0.00 SEK |
2012-04-23 | Årsstämma 2012 |
2012-04-23 | Kvartalsrapport 2012-Q1 |
2012-02-09 | Bokslutskommuniké 2011 |
2011-11-29 | 15-7 2011 |
2011-10-28 | Kvartalsrapport 2011-Q3 |
2011-08-12 | Kvartalsrapport 2011-Q2 |
2011-04-18 | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023.
Moberg Pharma have submitted a full application, which offers the possibility of data exclusivity in Europe for up to ten years following market approval. The Swedish Medical Products Agency is the reference member state and will lead the review of the application. The company's goal is to receive its first market approval and launch MOB-015 in 2023.
"Submitting the Marketing Authorization Application in Europe is a key milestone in our journey to launch a new and improved nail fungus drug. MOB-015 is uniquely positioned through its high antifungal efficacy, since there is significant need for a treatment that truly cures the nail infection," says Anna Ljung, CEO of Moberg Pharma AB.
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on March 28[th], 2022.